Clinical trials: Phase I
Solid Tumor, Adult, Relapsed Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of…
- Conditions
- Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer
- Trial name
- NCT05662397
- Testing
- HST-1011, Cemiplimab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 77 people
- Sponsor
- HotSpot Therapeutics, Inc
Breast Cancer, Breast Neoplasm
A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
- Conditions
- Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
- Trial name
- NCT06075810
- Testing
- MBQ-167
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 48 people
- Sponsor
- MBQ Pharma
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumor
Food-Effect and Metabolism Study in Healthy Subjects
This study evaluates the food-effect of one-dose Fluzoparib in healthy subjects. The participants receive Fluzoparib 120mg in fed state in Period 1 followed by administration of Fluzoparib 120mg in fasted state in Period 2.
- Trial name
- NCT03062982
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Helicobacter Pylori Infection
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
This is a single center, open label, drug-drug interaction, Phase 1 study of TNP-2198 in approximately 32 healthy participants, includes 2 cohorts (16 participants per cohort): Midazolam cohort and Clarithromycin cohort.
- Trial name
- NCT06551623
- Testing
- Midazolam, Clarithromycin, TNP-2198
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Inc.
Advanced Liver Cancer
OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer
An open-label dose-escalation phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of OH2 injection via transcatheter Intraarterial infusion in patients with advanced hepatocellular carcinoma
- Trial name
- NCT05698459
- Testing
- OH2 injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Healthy Subjects
Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin
- Trial name
- NCT03643575
- Testing
- Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Strength Chest Congestion, Organ-I- NR tablet
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Reckitt Benckiser Inc.
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Hematologic Malignancies
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.
- Trial name
- NCT01476657
- Testing
- IPI-145 (duvelisib)
- Where
- 4 sites in United States
- Volunteers
- 210 people
- Sponsor
- SecuraBio
Hepatic Impairment
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted…
- Trial name
- NCT05005312
- Testing
- PF-07321332, Ritonavir
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Advanced Solid Tumors
A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors
The main objective of the trial is to explore the safety and biological activity of NGR-hTNF. The safety will be established by clinical and laboratory assessment.
- Trial name
- NCT00419328
- Testing
- NGR-hTNF
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- AGC Biologics S.p.A.
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo
QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of…
- Trial name
- NCT01900171
- Testing
- QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
- Where
- France
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Quantum Genomics SA
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
T-lymphoblastic Lymphoma, T-ALL
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.
- Trial name
- NCT06136364
- Testing
- CAR-T
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Ulcerative Colitis (UC)
Safety, Tolerability and PK of ATTO 1091 in Healthy Adult Volunteers and Patients With Ulcerative Colitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics (PK) of ATTO-1091 in healthy adults and patients with ulcerative colitis.
- Trial name
- NCT07819799
- Testing
- ATTO-1091
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Obesity, Hepatic Insufficiency
Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. Decrease hepatic function can affect its elimination from the body via metabolism.
- Trial name
- NCT00645021
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
This study aims to assess any impact of VH4524184 on the pharmacokinetic (PK) profile of an ethinyl estradiol (EE) and norethindrone acetate (NEA) containing oral contraceptive (OC) administered to healthy adult female…
- Trial name
- NCT06310616
- Testing
- VH4524184, Loestrin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).
- Trial name
- Opti-GAIN (NCT07392255)
- Testing
- CTx001
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.